Management of microsatellite instability high (MSI-H) gastroesophageal adenocarcinoma

KI Zhou, BA Hanks, JH Strickler - Journal of Gastrointestinal Cancer, 2024 - Springer
Background Gastroesophageal cancer is a major cause of cancer-related mortality
worldwide. Treatment of both early stage and advanced disease remains highly reliant on …

Management of non-colorectal digestive cancers with microsatellite instability

M Zhu, Z Jin, JM Hubbard - Cancers, 2021 - mdpi.com
Simple Summary Microsatellite instability (MSI) is an established predictive biomarker for
immune checkpoint inhibitors with potential prognostic value in different types of tumors. Its …

Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer

CR Oh, EJ Kim, H Chae, YS Park, MH Ryu, HD Kim… - Gastric Cancer, 2024 - Springer
Background We examined the impact of mismatch repair (MMR) status on efficacy of first-
line fluoropyrimidine plus platinum (FP) chemotherapy in patients with HER2-negative …

Creation of a quality payment program measure for mismatch repair or microsatellite instability biomarker testing status in colorectal, endometrial, gastroesophageal …

GT Bocsi, J Laudadio, R Jain… - … of Pathology & …, 2024 - meridian.allenpress.com
Context.—Quality measures that are supported by evidence-based clinical practice
guidelines are preferred for assessing the quality of pathologists' practices. Careful testing of …

Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair

YG Park, HD Kim, J Hyung, YS Park, MH Ryu - Gastric Cancer, 2024 - Springer
Background We aimed to investigate clinicopathologic factors leading to different clinical
outcomes in patients with deficient mismatch repair protein (d-MMR) gastric cancer (GC) …

[HTML][HTML] Genomic Medicine in the Developing World: Cancer Spectrum, Cumulative Risk and Survival Outcomes for Lynch Syndrome Variant Heterozygotes with …

L Ndou, R Chambuso, U Algar, A Boutall, P Goldberg… - Biomedicines, 2024 - mdpi.com
Background: Although genetic testing has improved our ability to diagnose Lynch syndrome
(LS), there is still limited information on the extent of variations in the clinical and genetic …

Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment

S Kawatoko, K Kohashi, T Torisu, T Sasaki… - … -Research and Practice, 2022 - Elsevier
Solid-type poorly differentiated adenocarcinoma (solid-type-PDA) of the stomach is a unique
histological subtype of “tubular adenocarcinoma”, but little is known about its …

Prevalence and spectrum of germline pathogenic variants in cancer susceptibility genes among mexican patients with exocrine pancreatic cancer

JL Rodríguez-Olivares, TN Kimball, JM Jeter… - Pancreatology, 2024 - Elsevier
Background Although universal germline genetic testing is recommended for patients with
exocrine pancreatic cancer (PC), access to genetic testing remains limited in low-and middle …

[HTML][HTML] A narrative review of the evolving landscape of the management of metastatic gastric cancer: the role of targeted therapies

GM Delgado-Ramos, J Fitzsimons… - Journal of …, 2023 - ncbi.nlm.nih.gov
Methods We performed an extensive review of articles in the PubMed database pertaining to
targeted therapies and immunotherapies in the treatment of metastatic gastric cancer …

Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers

A Yamada, Y Doi, S Minamiguchi, T Kondo… - International Journal of …, 2024 - Springer
Background Lynch syndrome (LS) is a hereditary cancer syndrome caused by pathogenic
germline variants in mismatch repair (MMR) genes, which predisposes to various types of …